Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + vinorelbine + cyclophosphamide + capecitabine
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Adebry + VEX is a combination therapeutic regimen consisting of the PD-L1 monoclonal antibody adebrelimab (Adebry) and the metronomic chemotherapy combination VEX (vinorelbine, cyclophosphamide, and capecitabine). Adebrelimab is a humanized IgG4 monoclonal antibody that targets programmed death-ligand 1 (PD-L1), preventing its interaction with PD-1 and B7.1 receptors to restore T-cell mediated anti-tumor immunity. The VEX regimen utilizes low-dose, frequent administration (metronomic) of vinorelbine (a vinca alkaloid), cyclophosphamide (an alkylating agent), and capecitabine (a fluoropyrimidine prodrug) to exert anti-angiogenic and immunomodulatory effects while minimizing toxicity. This combination is primarily investigated for advanced breast cancer, including triple-negative breast cancer (TNBC) and HER2-negative breast cancer with brain metastases.
- Brand names
- NavelbineEndoxanXeloda
- Other names
- Adebry + VEXSHR-1316 + VEXPD-L1 + VEX
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD274 (Programmed cell death protein 1 ligand 1)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on adebrelimab + vinorelbine + cyclophosphamide + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + vinorelbine + cyclophosphamide + capecitabine.